Patents by Inventor Malcolm A. Carter
Malcolm A. Carter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240115728Abstract: The disclosure provides nanoemulsion compositions and methods of making and using thereof to deliver a bioactive agent such as a nucleic acid to a subject. The nanoemulsion composition comprises a hydrophobic core based on inorganic nanoparticles in a lipid nanoparticle that allows imaging as well as delivering nucleic acids. Methods of using these particles for treatment and vaccination are also provided.Type: ApplicationFiled: December 20, 2023Publication date: April 11, 2024Inventors: Amit KHANDHAR, Steven REED, Malcolm DUTHIE, Jesse ERASMUS, Darrick CARTER, Bryan J. BERUBE
-
Patent number: 8853204Abstract: A pharmaceutical composition which comprises a pharmaceutically acceptable carrier or diluent and: (a) an inhibitor of the RSV fusion protein; and (b) a benzodiazepine derivative capable of inhibiting RSV replication is found to be highly active against RSV.Type: GrantFiled: March 18, 2005Date of Patent: October 7, 2014Assignee: Arrow Therapeutics LimitedInventors: Kenneth Powell, Richard Kelsey, Malcolm Carter, Dagmar Alber, Lara Wilson, Elisa Henderson, Phil Chambers, Debra Taylor, Stan Tyms, Verity Dowdell
-
Patent number: 8119630Abstract: Benzodiazepine derivative of formula (I), and pharmaceutically acceptable salts thereof, are found to be active against RSV Formula (I) Wherein: —R1 represents C1-6 alkyl, aryl or heteroaryl; —R2 represents hydrogen or C1-6 alkyl; -each R3 is the same or different and represents halogen, hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio C1-6 haloalkyl, C1-6 haloalkoxy, amino, mono(C1-6 alkyl)amino, di(C1-6 alkyl)amino, nitro, cyano, —CO2R?, CONR?R?, —NH—CO—R?, —S(O)R?, —S(O)2R?, —NH—S(O)2R?, —S(O)NR?R? or —S(O)2NR?R? wherein each R? and R? is the same or different and represents hydrogen or C1-6 alkyl; -n is from 0 to 3; R4 represents hydrogen or C1-6 alkyl; —R6 represents C1-6 alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C1-6 alkyl)-, heteroaryl-(C1-6 alkyl)-, carbocyclyl-(C1-6 alkyl)-, heterocyclyl-(C1-6 alkyl)-, aryl-C(O)—C(O)—, heteroaryl-C(O)—C(O)—, carbocyclyl-C(O)—C(O)—, heterocyclyl-C(O)—C(O)— or, —XR6; —X represents —CO—, —S(O)— or —S(0)2—; and —R6 represents C1-6 alkyl, hydroxy, C1-6 alkType: GrantFiled: June 2, 2009Date of Patent: February 21, 2012Assignee: Arrow Therapeutics LimitedInventors: Malcolm Carter, Elisa Henderson, Richard Kelsey, Lara Wilson, Phil Chambers, Debra Taylor, Stan Tyms
-
Publication number: 20100015063Abstract: Benzodiazepine derivative of formula (I), and pharmaceutically acceptable salts thereof, are found to be active against RSV Formula (I) Wherein: —R1 represents C1-6 alkyl, aryl or heteroaryl; —R2 represents hydrogen or C1-6 alkyl; -each R3 is the same or different and represents halogen, hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio C1-6 haloalkyl, C1-6 haloalkoxy, amino, mono(C1-6 alkyl)amino, di(C1-6 alkyl)amino, nitro, cyano, —CO2R?, CONR?R?, —NH—CO—R?, —S(O)R?, —S(O)2R?, —NH—S(O)2R?, —S(O)NR?R? or —S(O)2NR?R? wherein each R? and R? is the same or different and represents hydrogen or C1-6 alkyl; -n is from 0 to 3; R4 represents hydrogen or C1-6 alkyl; —R6 represents C1-6 alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C1-6 alkyl)-, heteroaryl-(C1-6 alkyl)-, carbocyclyl-(C1-6 alkyl)-, heterocyclyl-(C1-6 alkyl)-, aryl-C(O)—C(O)—, heteroaryl-C(O)—C(O)—, carbocyclyl-C(O)—C(O)—, heterocyclyl-C(O)—C(O)— or, —XR6; —X represents —CO—, —S(O)— or —S(0)2—; and —R6 represents C1-6 alkyl, hydroxy, C1-6 alkType: ApplicationFiled: June 2, 2009Publication date: January 21, 2010Applicant: Arrow Therapeutics LimitedInventors: Malcolm Carter, Elisa Henderson, Richard Kelsey, Lara Wilson, Phil Chambers, Debra Taylor, Stan Tyms
-
Patent number: 7582624Abstract: Benzodiazepine derivative of formula (I), and pharmaceutically acceptable salts thereof, are found to be active against RSV.Type: GrantFiled: September 22, 2003Date of Patent: September 1, 2009Assignee: Arrow Therapeutics LimitedInventors: Malcolm Carter, Philip Chambers, Verity Dowdell, Elisa Ann Henderson, Richard David Kelsey, Debra Taylor, Stanley Tyms, Lara Wilson
-
Publication number: 20080139536Abstract: Use of a compound which is (a) a benzodiazepine derivative of the formula (I) or an N-oxide thereof or (b) a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in treating or preventing an RSV infection wherein: —R1 represents C1-6 alkyl, aryl or heteroaryl; —R2 represents hydrogen or C1-6 alkyl; each R3 is the same or different and represents halogen, hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C1-6 haloalkyl, C1-6 haloalkoxy, amino, mono(C1-6 alkyl)amino, di(C1-6alkyl)amino, vitro, cyano, —CO2R?, —CONR?R?, —NH—CO—R?, —S(O)R?, —S(O)2R?, —NH—S(O)2R?, —S(O)NR?R? or —S(O)2NR?R?, wherein each R? and R? is the same or different and represents hydrogen or C1-6 alkyl; n is from O to 3; R4 represents hydrogen or C1-6 alkyl; X represents —CO—, —CO—NR?—, —S(O)— or —S(O)2—, wherein R? is hydrogen or a C1-C6 alkyl group; and R5 represents a heteroaryl or heterocyclyl group which is substituted by a C1C6 hydroxyalkyl group or a —(C1-C4 alkyl)-X1—(C1-C4 alkyl)-X2—(C1-C4 alkyl} groupType: ApplicationFiled: March 18, 2005Publication date: June 12, 2008Applicant: Novartis Pharmaceuticals CorporationInventors: Verity Dowdell, Richard Kelsey, Malcolm Carter, Dagmar Alber, Elisa Henderson
-
Publication number: 20070293482Abstract: A process for producing a compound which is a benzodiazepine derivative of formula: (I) wherein: represents or R1 represents C1-6 alkyl, aryl or heteroaryl; each R3 is the same or different and represents halogen, hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C1-6 haloalkyl, C1-6 haloalkoxy, amino, mono(C1-6 alkyl)amino, di(C1-6 alkyl)amino, nitro, cyano, —CO2R?, —CONR?R?, —NH—CO—R?, —S(O)R?, —S(O)2R?, —NH—S(O)2R?, —S(O)NR?R? or —S(O)2NR?R?, wherein each R? and R? is the same or different and represents hydrogen or C1-6 alkyl; n is from 0 to 3; X represents —NH—, —N(C1-C6alkyl)-, —CO—, —CO—NR?—, —S(O)— or —S(O)2—, wherein R? is hydrogen or a C1-C6 alkyl group; and R4 represents hydrogen; or —CO—R4? or —CO—NH—R4 ?, wherein R4 ? is a C1-C6 alkyl, C1-C6 hydroxyalkyl, aryl, heteroaryl, carbocyclyl or heterocyclyl group, which group is substituted by a C1-C6 hydroxyalkyl, aryl, heteroaryl, carbocyclyl or heterocyclyl group or a —(C1-C4 alkyl)-X1—(C1-C4 alkyl)-X2—(C1-C4 alkyl) group, wherein X1 represents —Type: ApplicationFiled: March 21, 2005Publication date: December 20, 2007Applicant: Novartis Pharmaceuticals CorporationInventors: Verity Dowdell, Richard Kelsey, Malcolm Carter, Elisa Henderson
-
Publication number: 20070238875Abstract: A process for the preparation of a compound of formula (I) comprising the steps: (a) reacting a compound of formula (II) wherein L and L? are suitable leaving groups, with a compound of formula (III) UNH2??(III) to prepare a compound of formula (IV) and subsequently (b) substituting the group R1 by replacement of the leaving group L?.Type: ApplicationFiled: May 23, 2007Publication date: October 11, 2007Inventors: Malcolm CARTER, George Cockerill, Stephen Guntrip, Karen Lackey, Kathryn Smith
-
Publication number: 20070185096Abstract: A pharmaceutical composition which comprises a pharmaceutically acceptable carrier or diluent and: (a) an inhibitor of the RSV fusion protein; and (b) a benzodiazepine derivative capable of inhibiting RSV replication is found to be highly active against RSV.Type: ApplicationFiled: March 18, 2005Publication date: August 9, 2007Applicant: Novartis Pharmaceuticals CorporationInventors: Kenneth Powell, Richard Kelsey, Malcolm Carter, Verity Dowdell, Dagmar Alber, Elisa Henderson
-
Publication number: 20070142403Abstract: A pharmaceutical composition which comprises a pharmaceutically acceptable carrier or diluent and: (a) an inhibitor of the RSV fusion protein; and (b) a benzodiazepine derivative capable of inhibiting RSV replication is found to be highly active against RSV.Type: ApplicationFiled: March 18, 2005Publication date: June 21, 2007Applicant: Novartis Pharmaceuticala CorporationInventors: Kenneth Powell, Richard Kelsey, Malcolm Carter, Dagmar Alber, Lara Wilson, Elisa Henderson, Phil Chambers, Debra Taylor, Stan Tyms, Verity Dowdell
-
Patent number: 7161902Abstract: Congestion control in a communications network, e.g. an Internet Protocol (IP) network, is effected by controlling the egress rate of traffic from the output buffer of the system routers or switches. The traffic egressing from an output buffer is sampled at sequential intervals to determine a bit rate at each interval. An autocorrelation function is calculated from these samples and is used to provide an estimated statistical measure or parameter indicative of congestion and related to a long range dependence of the traffic. A calculation is then made as to whether an increase or a decrease in the buffer output rate would result in a decrease in the congestion parameter, and the buffer output rate is adjusted accordingly.Type: GrantFiled: May 28, 2002Date of Patent: January 9, 2007Assignee: Nortel Networks LimitedInventors: Malcolm Carter, David Ireland, Kevin Warbrick, Jon Weil, Peter Hamer, Richard Clegg, Arthur Clune
-
Publication number: 20060040923Abstract: Benzodiazepine derivative of formula (I), and pharmaceutically acceptable salts thereof, are found to be active against RSV.Type: ApplicationFiled: September 22, 2003Publication date: February 23, 2006Inventors: Malcolm Carter, Elisa Henderson, Richard Kelsey, Lara Wilson, Phil Chambers, Debra Taylor, Stan Tyms
-
Publication number: 20050282845Abstract: Methods for the treatment of pain, fever, inflammation of a variety of conditions and diseases.Type: ApplicationFiled: June 23, 2005Publication date: December 22, 2005Inventors: Malcolm Carter, Alan Naylor, Martin Pass, Jeremy Payne, Neil Pegg
-
Publication number: 20050130996Abstract: A process for the preparation of a compound of formula (I) comprising the steps: (a) reacting a compound of formula (II) wherein L and L? are suitable leaving groups, with a compound of formula (III) UNH2??(III) to prepare a compound of formula (IV) and subsequently (b) substituting the group R1 by replacement of the leaving group L?.Type: ApplicationFiled: February 3, 2005Publication date: June 16, 2005Inventors: Malcolm Carter, George Cockerill, Stephen Guntrip, Karen Lackey, Kathryn Smith
-
Publication number: 20040102466Abstract: A compound of formula (I) and pharmaceutically acceptable derivatives thereof, in which R1 is H or C1-4alkyl; R2 is R3 is C1-6alkyl or NH2. Compounds of formula (I) are potent and selective inhibitors of COX-2 and are of use in the treatment of the pain, fever, inflammation of a variety of conditions and diseases.Type: ApplicationFiled: June 25, 2003Publication date: May 27, 2004Inventors: Malcolm Carter, Alan Naylor, Martin Pass, Jeremy Payne, Neil Pegg
-
Publication number: 20030035374Abstract: Congestion control in a communications network, e.g. an Internet Protocol (IP) network, is effected by controlling the egress rate of traffic from the output buffer of the system routers or switches. The traffic egressing from an output buffer is sampled at sequential intervals to determine a bit rate at each interval. An autocorrelation function is calculated from these samples and is used to provide an estimated statistical measure or parameter indicative of congestion and related to a long range dependence of the traffic. A calculation is then made as to whether an increase or a decrease in the buffer output rate would result in a decrease in the congestion parameter, and the buffer output rate is adjusted accordingly.Type: ApplicationFiled: May 28, 2002Publication date: February 20, 2003Inventors: Malcolm Carter, David Ireland, Kevin Warbrick, Jon Weil, Peter Hamer, Richard Clegg, Arthur Clune
-
Patent number: 5786473Abstract: A process for the preparation of the compound of formula (I) ##STR1## or a salt thereof which comprises reducing the compound of formula (II) ##STR2## or a salt thereof. The novel intermediate of formula (II) and processes for preparing it are also described.Type: GrantFiled: March 19, 1997Date of Patent: July 28, 1998Assignee: Glaxo Group LimitedInventors: Philip Blatcher, Malcolm Carter, Roy Hornby, Martin Richard Owen
-
Patent number: 5659040Abstract: A process for the preparation of the compound of formula (I) ##STR1## or a salt thereof which comprises reducing the compound of formula (II) ##STR2## or a salt thereof. The novel intermediate of formula (II) and processes for preparing it are also described.Type: GrantFiled: February 29, 1996Date of Patent: August 19, 1997Assignee: Glaxo Group LimitedInventors: Philip Blatcher, Malcolm Carter, Roy Hornby, Martin Richard Owen
-
Patent number: 5510350Abstract: The invention provides compounds of formula (I): ##STR1## or a physiologically acceptable salt or solvate thereof wherein R.sup.1 represents a hydrogen atom or a halogen atom or a group selected from C.sub.1-6 alkyl and C.sub.1-6 alkoxy;R.sup.2 represents a phenyl group substituted by a group selected from ##STR2## and optionally further substituted by one or two substituents selected from halogen atoms, C.sub.1-6 alkoxy, hydroxy, and C.sub.1-6 alkyl;R.sup.3 represents the group ##STR3## R.sup.4 and R.sup.5, which may be the same or different, each independently represent a hydrogen atom or a halogen atom or a group selected from hydroxy, C.sub.1-6 alkoxy and C.sub.1-6 alkyl;R.sup.6 represents a hydrogen atom or a group selected from --NR.sup.9 R.sup.10 and a C.sub.1-6 alkyl group optionally substituted by one or two substituents selected from C.sub.1-6 alkoxy, hydroxy, C.sub.1-6 acyloxy and --SO.sub.2 R.sup.11 ;R.sup.7, R.sup.8 and R.sup.Type: GrantFiled: May 3, 1994Date of Patent: April 23, 1996Assignee: Glaxo Group LimitedInventors: Alexander W. Oxford, William L. Mitchell, John Bradshaw, John W. Clitherow, Malcolm Carter
-
Patent number: 5340810Abstract: The invention provides compounds of formula (I): ##STR1## or a physiologically acceptable salt or solvate thereof wherein R.sup.1 represents a hydrogen atom or a halogen atom or a group selected from C.sub.1-6 alkyl and C.sub.1-6 alkoxy;R.sup.2 represents a phenyl group substituted by a group selected from ##STR2## and optionally further substituted by one or two substituents selected from halogen atoms, C.sub.1-6 alkoxy, hydroxy, and C.sub.1-6 alkyl;R.sup.3 represents the group ##STR3## R.sup.4 and R.sup.5, which may be the same or different each independently represent a hydrogen atom or a halogen atom or a group selected from hydroxy, C.sub.1-6 alkoxy and C.sub.1-6 alkyl;R.sup.6 represents a hydrogen atom or a group selected from --NR.sup.9 R.sup.10 and a C.sub.1-6 alkyl group optionally substituted by one or two substituents selected from C.sub.1-6 alkoxy, hydroxy, C.sub.1-6 acyloxy and --SO.sub.2 R.sup.11 ;R.sup.7, R.sup.8 and R.sup.Type: GrantFiled: September 17, 1992Date of Patent: August 23, 1994Assignee: Glaxo Group LimitedInventors: John W. Clitherow, Malcolm Carter